Physician profile
Robert A Hozman
NPI 1659308237
$151,793.90
in general payments reported to CMS, 2019-2025
67 companies · $19K in 2025
The $19K reported for 2025 was more than what 92% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $32K · 2021: $16K · 2022: $15K · 2023: $17K · 2024: $19K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $27K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Consulting Fee: $5,035 · Education: $165 · Travel and Lodging: $95.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $27,431.42 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,465.00 |
| Consulting Fee | $5,035.00 |
| Education | $164.76 |
| Travel and Lodging | $95.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $52,960.67 | 2019-2025 | Otezla, Otezla, Tavneos |
| Horizon Therapeutics Plc | $19,891.83 | 2019-2023 | Krystexxa |
| Celgene Corporation | $11,602.57 | 2019-2024 | Orencia |
| Abbvie INC. | $10,551.28 | 2019-2025 | |
| Glaxosmithkline, LLC. | $10,006.58 | 2019-2025 | Benlysta, Trelegy Ellipta, Nucala |
| Novartis Pharmaceuticals Corporation | $9,698.44 | 2019-2025 | |
| Pfizer INC. | $5,435.50 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $5,064.54 | 2019-2025 | Orencia, Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $3,587.58 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Ucb, INC. | $3,346.08 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $3,281.19 | 2019-2025 | Tremfya |
| Mallinckrodt Hospital Products INC. | $2,239.64 | 2020-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,926.27 | 2019-2025 | Jardiance, Cyltezo, Ofev |
| Novo Nordisk INC | $1,736.68 | 2019-2025 | Ozempic, Rybelsus |
| Ani Pharmaceuticals, INC. | $1,219.12 | 2022-2025 | Purified Cortrophin Gel |
Show all 62 companies
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hozman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.